Avenue Therapeutics, Inc.
ATXI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6,645 | $10,361 | $2,698 | $1,254 |
| G&A Expenses | $4,638 | $4,179 | $5,345 | $2,484 |
| SG&A Expenses | $4,638 | $4,179 | $5,345 | $2,484 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $11,283 | $14,540 | $8,043 | $3,738 |
| Operating Income | -$11,283 | -$14,540 | -$8,043 | -$3,738 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$413 | $4,052 | $4,440 | $7 |
| Pre-Tax Income | -$11,696 | -$10,488 | -$3,603 | -$3,731 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11,652 | -$10,377 | -$3,552 | -$3,731 |
| % Margin | – | – | – | – |
| EPS | -0.9 | -73.6 | -121.91 | -3.29 |
| % Growth | 98.8% | 39.6% | -3,605.5% | – |
| EPS Diluted | -0.9 | -73.48 | -121.91 | -3.29 |
| Weighted Avg Shares Out | 12,952 | 141 | 29 | 1,133 |
| Weighted Avg Shares Out Dil | 12,952 | 141 | 29 | 1,133 |
| Supplemental Information | – | – | – | – |
| Interest Income | $176 | $126 | $20 | $7 |
| Interest Expense | $0 | $0 | $1,160 | $0 |
| Depreciation & Amortization | $0 | $14,540 | $0 | $3,738 |
| EBITDA | -$11,696 | $4,052 | -$2,443 | $7 |
| % Margin | – | – | – | – |